Edition:
United States

Baxter International Inc (BAX.N)

BAX.N on New York Stock Exchange

58.64USD
26 May 2017
Change (% chg)

$-0.50 (-0.85%)
Prev Close
$59.14
Open
$59.07
Day's High
$59.10
Day's Low
$58.46
Volume
381,277
Avg. Vol
787,185
52-wk High
$59.41
52-wk Low
$42.22

Latest Key Developments (Source: Significant Developments)

Baxter International says in April became aware of criminal investigation by antitrust division of DOJ- SEC filing
Thursday, 4 May 2017 07:01pm EDT 

May 4 (Reuters) - Baxter International Inc ::in April 2017, co became aware of criminal investigation by U.S. DOJ, antitrust division and federal jury in U.S. District court for eastern district of Pennsylvania-filing.co and employee received subpoenas regarding manufacturing, selling, pricing and shortages of intravenous solutions and containers.  Full Article

Baxter International says received guidance from FDA clarifying regulatory pathway for new peritoneal dialysis technology
Wednesday, 3 May 2017 08:30am EDT 

May 3 (Reuters) - Baxter International Inc :Baxter International Inc - received guidance from FDA clarifying regulatory pathway for new peritoneal dialysis technology.Baxter International Inc - Baxter plans to have first patient on therapy with new system, as part of a clinical trial in 2018.Baxter International Inc - regulatory submission is expected in 2019 for new peritoneal dialysis technology.  Full Article

Baxter raises quarterly dividend
Tuesday, 2 May 2017 08:30am EDT 

May 2 (Reuters) - Baxter International Inc : :Increases quarterly dividend by 23 percent.Baxter raises quarterly dividend.Baxter International Inc - sets qtrly dividend of 13 cents per share.  Full Article

Baxter International Q1 revenue $2.5 billion
Wednesday, 26 Apr 2017 07:15am EDT 

April 26 (Reuters) - Baxter International Inc :Baxter reports first-quarter 2017 results and increases financial outlook for full-year 2017.Q1 GAAP earnings per share $0.50 from continuing operations.Q1 revenue $2.5 billion versus I/B/E/S view $2.43 billion.Q1 earnings per share view $0.51 -- Thomson Reuters I/B/E/S.Sees FY 2017 earnings per share $2.20 to $2.28 from continuing operations excluding items.Sees FY 2017 GAAP earnings per share $1.66 to $1.80.In Q2, expects flat sales growth on a reported basis, or approximately 2 percent on a constant currency basis.FY2017 earnings per share view $2.17 -- Thomson Reuters I/B/E/S.Baxter International - now expects sales growth of approximately 1 to 2 percent on a reported basis or 2 to 3 percent on a constant currency basis in 2017.Baxter International - expects sales growth of about 1 to 2 percent on a reported basis or 2 to 3 percent on a constant currency basis for FY 2017.Baxter International says expects earnings from continuing operations, before special items, of $0.55 to $0.57 per diluted share in Q2.Qtrly adjusted earnings of $0.58 per share.Q2 earnings per share view $0.52, revenue view $2.56 billion -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $2.17, revenue view $10.20 billion -- Thomson Reuters I/B/E/S.  Full Article

Third Point sells 5.9 mln shares of Baxter International's common stock in block trade on Feb 28
Wednesday, 1 Mar 2017 11:44am EST 

: Third Point LLC says on Feb 28, it sold about 5.9 mln shares of Baxter International Inc's common stock in a block trade at $50.35 per share . Third Point LLC now owns about 46 million shares of Baxter International's common stock as of feb 28 - sec filing . Third Point LLC previously owned 51.9 million shares of Baxter International's common stock as of Dec 31, 2016 according to its 13-F filing disclosed in Feb .Third Point​ now owns 8.5 pct stake in Baxter International following the block trade.  Full Article

Baxter and Scinopharm announce partnership for generic oncology injectables
Tuesday, 28 Feb 2017 08:00am EST 

Baxter International Inc : Baxter and Scinopharm announce exclusive strategic partnership for generic oncology injectables . Baxter International Inc - under terms of partnership, Baxter and Scinopharm will collaborate on product development and manufacturing .Baxter International Inc - Baxter will hold commercialization rights, with products included in arrangement expected to launch beginning in 2020.  Full Article

Baxter debuts enteral nutrition ENFit syringe and accessory line in clinical nutrition week 2017
Thursday, 16 Feb 2017 08:30am EST 

Baxter International Inc - : Baxter debuts enteral nutrition ENFit syringe and accessory line during clinical nutrition week 2017 . Expansion of nutrition care portfolio to include new enteral ENFit syringe, accessory line for patients requiring tube feeding .Plans to launch its enteral ENFit syringes, accessories in US , Canada, select European countries, Australia, New Zealand in 2017.  Full Article

Baxter International reports Q4 earnings per share of $0.44
Wednesday, 1 Feb 2017 07:30am EST 

Baxter International Inc : Baxter reports 2016 fourth-quarter and full-year results . Sees Q1 2017 earnings per share $0.50 to $0.52 from continuing operations excluding items . Baxter International Inc says fourth-quarter revenue of $2.6 billion increased 2 percent on a reported and constant currency basis . Baxter International Inc says fourth-quarter GAAP earnings per share of $0.44; adjusted earnings per share of $0.57 increased 33 percent . Baxter International - worldwide sales totaled $2.6 billion in Q4, increase of 2 percent on reported and constant currency basis versus prior-year period . Baxter -renal sales totaled $1 billion in Q4, representing a 3 percent increase on a reported basis, and a 5 percent increase on a constant currency basis . Baxter International Inc sees Q1 GAAP earnings per share $0.39 - $0.42 . Baxter International - for FY 2017, expects sales to be comparable to prior-year period on reported basis, increase about 2 percent on constant currency basis . Baxter International Inc - for Q1, company expects sales growth of approximately 2 to 3 percent on a reported basis . Baxter International Inc sees Q1 adjusted earnings per share $0.50 - $0.52 . Baxter International Inc - expects earnings from continuing operations, before special items, of $2.10 to $2.18 per diluted share for full-year 2017 . Says expects 2017 underlying constant currency sales growth of approximately 4 percent.  Full Article

Baxter Q3 adj earnings per share $0.56 from continuing operations excluding items
Tuesday, 25 Oct 2016 07:00am EDT 

Baxter International Inc : Baxter reports third quarter 2016 results and increases financial outlook for full-year 2016 . Sees Q4 2016 earnings per share $0.49 to $0.52 from continuing operations excluding items . Q3 GAAP earnings per share $0.23 from continuing operations . Q3 sales $2.6 billion versus i/b/e/s view $2.55 billion . Q3 earnings per share view $0.45 -- Thomson Reuters I/B/E/S . Raises FY 2016 earnings per share view to $1.88 to $1.91 from continuing operations excluding items . Q3 adjusted earnings per share $0.56 from continuing operations excluding items . Sees Q4 sales up about 2 percent . Baxter international inc - raising its financial outlook for full-year 2016 including sales growth of approximately 2 percent on a reported basis . Fy2016 earnings per share view $1.72, revenue view $10.15 billion -- Thomson Reuters I/B/E/S . Sees earnings from continuing operations, before special items, of $1.88 to $1.91 per diluted share for full year . Fy2016 earnings per share view $1.72 -- Thomson Reuters I/B/E/S . Baxter International Inc - on an adjusted basis Baxter's Q3 income from continuing operations totaled $0.56 per diluted share .Baxter International Inc - for Q4, company expects sales growth of approximately 2 percent on both a reported and constant currency basis.  Full Article

Sunshine Heart buys Baxter's Aquadex product line
Monday, 8 Aug 2016 05:30am EDT 

Sunshine Heart Inc: Sunshine Heart announces strategic acquisition of Aquadex product line from Baxter and a new credit facility with Silicon Valley Bank . Under terms of agreement, Baxter received $4.0 million in cash and 1.0 million shares of Sunshine Heart common stock . Entered into a new $5.0 million facility to finance future working capital needs . Company repaid all amounts outstanding under its existing debt facility with Silicon Valley Bank ."Expect product line to be accretive in first year".  Full Article

More From Around the Web